Dr. Doebele on Significant Findings of Entrectinib in Patients With ROS1+ NSCLC

Video

Robert C. Doebele, MD, PhD, associate professor, Division of Medical Oncology, University of Colorado, discusses the significance of the results of a trial exploring entrectinib in patients with ROS1-positive non

Robert C. Doebele, MD, PhD, associate professor, Division of Medical Oncology, University of Colorado, discusses the significance of the results of a trial exploring entrectinib in patients with ROS1-positive non—small cell lung cancer (NSCLC).

The findings of the phase II clinical trial of entrectinib in ROS1-positive NSCLC achieved an objective response rate (ORR) of 78% and a median progression-free survival (PFS) of approximately 30 months, Doebele explains.

The significance of these results, Doebele adds, is that entrectinib could potentially be a central nervous system (CNS)-active tyrosine kinase inhibitor for ROS1-positive NSCLC. In this trial, there were 6 patients evaluated with CNS metastases, 5 of whom had a response and demonstrated an ORR of 83%. This is likely driving a longer PFS in these patients. In conclusion, this could potentially be a frontline option for patients with this molecular abnormality.

Related Videos
Patrick I. Borgen, MD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Reshma Lillaney Mahtani, DO
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center